Lets hope its more than a cut and paste as below from the last quarterly........no wonder the shorters have made the stock a favourite, billions touted in most announcements, yet nil to show for anything........
In parallel with completing enrolment and treatment of patients in these clinical trials, licensing activities are ongoing for all three products as part of Starpharma’s DEP® commercialisation strategy.
SPL Price at posting:
31.0¢ Sentiment: None Disclosure: Held
